Based on the presented symptoms, the most probable diagnosis is acute fatty liver of pregnancy. This is supported by the presence of jaundice, mild fever, elevated liver function tests, increased white blood cell count, coagulopathy, and steatosis on imaging. Acute fatty liver of pregnancy typically presents with non-specific symptoms such as fatigue, malaise, and nausea, whereas cholestasis of pregnancy is characterized by severe itching. The absence of abnormalities in hemoglobin, platelet count, and viral screening makes the diagnosis of HELLP syndrome or viral hepatitis unlikely. Additionally, pre-eclampsia is characterized by hypertension and proteinuria. It is important to note that placental ALP can cause an increase in serum ALP levels during pregnancy.

Liver Complications During Pregnancy

During pregnancy, there are several liver complications that may arise. One of the most common is intrahepatic cholestasis of pregnancy, which occurs in about 1% of pregnancies and is typically seen in the third trimester. Symptoms include intense itching, especially in the palms and soles, as well as elevated bilirubin levels. Treatment involves the use of ursodeoxycholic acid for relief and weekly liver function tests. Women with this condition are usually induced at 37 weeks to prevent stillbirth, although maternal morbidity is not typically increased.

Another rare complication is acute fatty liver of pregnancy, which may occur in the third trimester or immediately after delivery. Symptoms include abdominal pain, nausea and vomiting, headache, jaundice, and hypoglycemia. Severe cases may result in pre-eclampsia. ALT levels are typically elevated, and support care is the primary management until delivery can be performed once the patient is stabilized.

Finally, conditions such as Gilbert’s and Dubin-Johnson syndrome may be exacerbated during pregnancy. Additionally, HELLP syndrome, which stands for haemolysis, elevated liver enzymes, and low platelets, is a serious complication that can occur in the third trimester and requires immediate medical attention. Overall, it is important for pregnant women to be aware of these potential liver complications and to seek medical attention if any symptoms arise.

Diagnosis and Management of Pre-eclampsia in Pregnancy

Pre-eclampsia is a serious condition that can occur during pregnancy, characterized by hypertension, proteinuria, and edema. It can lead to various complications and is a leading cause of maternal death. Risk factors include nulliparity, previous history of pre-eclampsia, family history, and certain medical conditions. Diagnosis is made by testing for proteinuria and monitoring blood pressure. Treatment involves close monitoring, medication, and delivery of the baby. Complications can include HELLP syndrome and eclampsia. Testing for liver function and performing a CTG can aid in management, but will not lead to the diagnosis. Early identification and management are crucial in preventing adverse outcomes.

If a pregnant woman who is not immune to chickenpox is exposed to the virus, it is crucial to offer varicella-zoster immunoglobulin (VZIG) within 10 days of the exposure to reduce the risk of foetal varicella-zoster syndrome and potential complications for the mother. However, if the woman is under 20 weeks pregnant, oral acyclovir is not recommended as there is limited evidence for its efficacy in this situation. Giving both VZIG and oral acyclovir is impractical and inappropriate, especially since the woman has already been exposed to chickenpox. If the woman develops chickenpox before 20 weeks gestation, acyclovir may be considered, but VZIG should still be given to reduce the chance of severe infection. It is important to note that VZIG should be given before symptoms develop and is only effective up to 10 days post-exposure. Therefore, waiting for symptoms to appear before giving VZIG is not recommended.

Chickenpox exposure in pregnancy can pose risks to both the mother and fetus, including fetal varicella syndrome. Post-exposure prophylaxis (PEP) with varicella-zoster immunoglobulin (VZIG) or antivirals should be given to non-immune pregnant women, with timing dependent on gestational age. If a pregnant woman develops chickenpox, specialist advice should be sought and oral acyclovir may be given if she is ≥ 20 weeks and presents within 24 hours of onset of the rash.

The results are typical of placenta praevia, according to the findings.
The RCOG suggests transvaginal ultrasound as it enhances the precision of placental positioning and is deemed to be safe.

Understanding Placenta Praevia

Placenta praevia is a condition where the placenta is located wholly or partially in the lower uterine segment. It is a relatively rare condition, with only 5% of women having a low-lying placenta when scanned at 16-20 weeks gestation. However, the incidence at delivery is only 0.5%, as most placentas tend to rise away from the cervix.

There are several factors associated with placenta praevia, including multiparity, multiple pregnancy, and embryos implanting on a lower segment scar from a previous caesarean section. Clinical features of placenta praevia include shock in proportion to visible loss, no pain, a non-tender uterus, abnormal lie and presentation, and a usually normal fetal heart. Coagulation problems are rare, and small bleeds may occur before larger ones.

Diagnosis of placenta praevia should not involve digital vaginal examination before an ultrasound, as this may provoke severe haemorrhage. The condition is often picked up on routine 20-week abdominal ultrasounds, but the Royal College of Obstetricians and Gynaecologists recommends the use of transvaginal ultrasound for improved accuracy and safety. Placenta praevia is classified into four grades, with grade IV being the most severe, where the placenta completely covers the internal os.

In summary, placenta praevia is a rare condition that can have serious consequences if not diagnosed and managed appropriately. It is important for healthcare professionals to be aware of the associated factors and clinical features, and to use appropriate diagnostic methods for accurate grading and management.

Breast Conditions in Lactating Women

Lactating women may experience various breast conditions, including mastitis, breast abscess, cellulitis, engorged breasts, and full breasts.

Mastitis is typically caused by a blocked duct or ascending infection from nipple trauma during breastfeeding. Symptoms include unilateral pain, breast engorgement, and erythema. Treatment involves analgesia, reassurance, and continuing breastfeeding. Antibiotics may be necessary if symptoms persist or a milk culture is positive.

Breast abscess presents as a painful lump in the breast tissue, often with systemic symptoms such as fever and malaise. Immediate treatment is necessary to prevent septicaemia.

Cellulitis is an acute bacterial infection of the breast skin, presenting with erythema, tenderness, swelling, and blister formation. Non-specific symptoms such as rigors, fevers, and malaise may also occur.

Engorged breasts can be primary or secondary, causing bilateral breast pain and engorgement. The skin may appear shiny, and the nipple may appear flat due to stretching.

Full breasts are associated with lactation and cause warm, heavy, and hard breasts. This condition typically occurs between the 2nd and 6th day postpartum.

Postpartum haemorrhage caused by uterine atony can be treated with various medical options such as oxytocin, ergometrine, carboprost, and misoprostol.

The most common reason for primary postpartum haemorrhage is an atonic uterus. To prevent excessive blood loss, the patient should be advised to receive Syntometrine or oxytocin to stimulate uterine contractions. During the third stage of labour, cord traction should be performed, and the uterus should be massaged after the placenta is delivered. If these measures are ineffective, additional interventions such as blood transfusion and manual removal of the placenta may be necessary. Although breastfeeding can cause uterine contractions, it is not recommended in this case due to the severity of the bleeding.

Understanding Postpartum Haemorrhage

Postpartum haemorrhage (PPH) is a condition where a woman experiences blood loss of more than 500 ml after giving birth vaginally. It can be classified as primary or secondary. Primary PPH occurs within 24 hours after delivery and is caused by the 4 Ts: tone, trauma, tissue, and thrombin. The most common cause is uterine atony. Risk factors for primary PPH include previous PPH, prolonged labour, pre-eclampsia, increased maternal age, emergency Caesarean section, and placenta praevia.

In managing PPH, it is important to involve senior staff immediately and follow the ABC approach. This includes two peripheral cannulae, lying the woman flat, blood tests, and commencing a warmed crystalloid infusion. Mechanical interventions such as rubbing up the fundus and catheterisation are also done. Medical interventions include IV oxytocin, ergometrine, carboprost, and misoprostol. Surgical options such as intrauterine balloon tamponade, B-Lynch suture, ligation of uterine arteries, and hysterectomy may be considered if medical options fail to control the bleeding.

Secondary PPH occurs between 24 hours to 6 weeks after delivery and is typically due to retained placental tissue or endometritis. It is important to understand the causes and risk factors of PPH to prevent and manage this life-threatening emergency effectively.

Recommendations for Feeding Low-Birthweight Infants

Low-birthweight infants, those with a birthweight of less than 2,500 g, should be exclusively breastfed for the first six months of life, according to WHO recommendations. If the mother’s milk is not available, donor human milk should be sought. If that is not possible, standard formula milk can be used. There is no difference in the duration of exclusive breastfeeding between low-birthweight and normal-weight infants. Daily vitamin A supplementation is not currently recommended for low-birthweight infants, but very low-birthweight infants should receive daily supplementation of vitamin D, calcium, and phosphorus. Low-birthweight infants who are able to breastfeed should start as soon as possible after birth, once they are clinically stable.

In the case of an umbilical cord prolapse, it is important to push the presenting part of the fetus back into the uterus to prevent compression of the cord and subsequent fetal distress. This can be aided by retro-filling the bladder with saline and positioning the mother on all fours. Administering oxytocin infusion or tocolytics to stop uterine contractions is not recommended as they can worsen the situation. The McRoberts manoeuvre is also not applicable in this scenario. It is crucial to manage the situation promptly to prevent further harm to the fetus.

Understanding Umbilical Cord Prolapse

Umbilical cord prolapse is a rare but serious complication that can occur during delivery. It happens when the umbilical cord descends ahead of the presenting part of the fetus, which can lead to compression or spasm of the cord. This can cause fetal hypoxia and potentially irreversible damage or death. Certain factors increase the risk of cord prolapse, such as prematurity, multiparity, polyhydramnios, twin pregnancy, cephalopelvic disproportion, and abnormal presentations like breech or transverse lie.

Around half of all cord prolapses occur when the membranes are artificially ruptured. Diagnosis is usually made when the fetal heart rate becomes abnormal and the cord is palpable vaginally or visible beyond the introitus. Cord prolapse is an obstetric emergency that requires immediate management. The presenting part of the fetus may be pushed back into the uterus to avoid compression, and the cord should be kept warm and moist to prevent vasospasm. The patient may be asked to go on all fours or assume the left lateral position until preparations for an immediate caesarian section have been carried out. Tocolytics may be used to reduce uterine contractions, and retrofilling the bladder with saline can help elevate the presenting part. Although caesarian section is the usual first-line method of delivery, an instrumental vaginal delivery may be possible if the cervix is fully dilated and the head is low.

In conclusion, umbilical cord prolapse is a rare but serious complication that requires prompt recognition and management. Understanding the risk factors and appropriate interventions can help reduce the incidence of fetal mortality associated with this condition.

This patient is suffering from severe pre-eclampsia, evidenced by moderate hypertension and symptoms of headache and vomiting. According to NICE guidelines, delivery should be carried out within 24-48 hours for women with pre-eclampsia and mild to moderate hypertension after 37 weeks. Magnesium sulphate is recommended for the treatment of severe hypertension or pre-eclampsia in women who have already experienced seizures. IV magnesium sulphate should also be considered if delivery is planned within 24 hours or if there is a risk of eclampsia. Although IV hydralazine may lower blood pressure, immediate delivery and protection against eclampsia are required due to the patient’s presenting symptoms. IM beclomethasone is unnecessary as the patient is past 36 weeks. IV calcium gluconate is used to treat magnesium toxicity and is not indicated in this case. While delivery should be planned, the patient also requires protection against the development of eclampsia and seizures.

Pre-eclampsia is a condition that occurs during pregnancy and is characterized by high blood pressure, proteinuria, and edema. It can lead to complications such as eclampsia, neurological issues, fetal growth problems, liver involvement, and cardiac failure. Severe pre-eclampsia is marked by hypertension, proteinuria, headache, visual disturbances, and other symptoms. Risk factors for pre-eclampsia include hypertension in a previous pregnancy, chronic kidney disease, autoimmune disease, diabetes, chronic hypertension, first pregnancy, and age over 40. Aspirin may be recommended for women with high or moderate risk factors. Treatment involves emergency assessment, admission for observation, and medication such as labetalol, nifedipine, or hydralazine. Delivery of the baby is the most important step in management, with timing depending on the individual case.

The patient is likely suffering from obstetric cholestasis, which can increase the risk of premature birth and stillbirth. The main symptom is severe itching, and elevated serum bile acids are typically present. Liver function tests, including bilirubin levels, may not be reliable. The most effective treatment is ursodeoxycholic acid (UDCA), which is now mostly synthetic. While antihistamines and topical menthol creams can provide some relief, UDCA is more likely to improve outcomes.

Intrahepatic Cholestasis of Pregnancy: Symptoms and Management

Intrahepatic cholestasis of pregnancy, also known as obstetric cholestasis, is a condition that affects approximately 1% of pregnancies in the UK. It is characterized by intense itching, particularly on the palms, soles, and abdomen, and may also result in clinically detectable jaundice in around 20% of patients. Raised bilirubin levels are seen in over 90% of cases.

The management of intrahepatic cholestasis of pregnancy typically involves induction of labor at 37-38 weeks, although this practice may not be evidence-based. Ursodeoxycholic acid is also widely used, although the evidence base for its effectiveness is not clear. Additionally, vitamin K supplementation may be recommended.

It is important to note that the recurrence rate of intrahepatic cholestasis of pregnancy in subsequent pregnancies is high, ranging from 45-90%. Therefore, close monitoring and management are necessary for women who have experienced this condition in the past.